I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

2023 ASCO Annual Meeting

Coming soon
04:45 PM
Duration 6mins E450
Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study
Petra Budde, Delvys Rodriguez Abreu, Hans-Dieter Zucht, Divya Shrivastava, Annika L. Kilian, Elen Hoglander, Stefaniya Shoshkova, Marija Markovic, Monika Kaul, Jose Vicente Cardona, G Scott Chandler, Rajat Mohindra
04:54 PM
Duration 12mins Virtual
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
Richard S. Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, Daneng, Adam Burgoyne, Christopher Cotter, Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, Tirupathi Rao Edubilli, Ed Gane
11:30 AM
Duration 12mins Hall D1
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: Phase III CONTACT-03 study
Choueiri T, Piotr T, Albiges L, Suárez C, Voss M, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Chan K, Powles T, Gupta S, Kalaitzidou M, Scheffold C, Pal K S, Mochalova A
Duration 12mins Arie Crown Theater
Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Masatoshi Kudo, Minshan Chen, Pierce Chow, Ahmed Kaseb, Han Chu Lee, Adam Yopp, Lars Becker, Sairy Hernandez, Bruno Kovic, Qinshu Lian, Ning Ma, Chun Wu, Shukui Qin, Ann-Lii Cheng
12:42 PM
Duration 12mins Hall D1
Overall survival by response to first-line induction treatment with atezolizumab + platinum/gemcitabine vs placebo + plt/gem in patients with metastatic urothelial carcinoma: updated data from the IMvigor130 OS final analysis
Grande E, Bamias A, Galsky MD, Kikuchi E, Davis ID, Arranz JA, Rezazadeh Kalebasty A, Garcia del Muro X, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Puente J, Li J-R, Lee C, Bernhard S, Nicholas A, Telliez J, De Santis M